Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

Review
.2010 Sep;127(3):271-82.
doi: 10.1016/j.pharmthera.2010.04.003. Epub 2010 May 11.

Sigma receptors: potential targets for a new class of antidepressant drug

Affiliations
Review

Sigma receptors: potential targets for a new class of antidepressant drug

James A Fishback et al. Pharmacol Ther.2010 Sep.

Abstract

Despite the widespread and devastating impact of depression on society, our current understanding of its pathogenesis is limited. Likewise, existing treatments are inadequate, providing relief to only a subset of people suffering from depression. The search for more effective antidepressant drugs includes the investigation of new molecular targets. Among them, current data suggests that sigma receptors are involved in multiple processes effecting antidepressant-like actions in vivo and in vitro. This review summarizes accumulated evidence supporting a role for sigma receptors in antidepressant effects and provides a conceptual framework for delineating their potential roles over the course of antidepressant treatment.

2010 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1. Hypothesized sequence of events for antidepressant actions
Classic antidepressant drugs produce effects which can be classified temporally into immediate, intermediate and delayed actions, with resulting functional changes associated at each stage.
Figure 2
Figure 2. Sigma receptors modulate numerous pathways implicated in the etiology or pathophysiology of depression
It is believed that Ca2+ modulation through sigma receptors can act upon pathways involved in neurite outgrowth, as well as gene regulation, specifically, ERK, MAPK and Akt pathways. It is hypothesized that sigma receptor-mediated modulation of IP3Rs at the MAM, also contributes to an increase in ATP production from the mitochondria, which may have profound effects on signaling within the cell which have not yet been fully studied. Sigma receptors have also been shown to modulate PKA pathways; sigma agonists have been shown to modulate the phosphorylation of CREB, indicative of effects on gene transcription. Sigma receptors also have known effects on the transmission of signaling via neurotransmitters; however these pathways have not been fully elucidated. Dashed lines indicate known and hypothesized effects of sigma receptors on signaling pathways believed to be involved in depression.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. Cmaj. 2009;180:305–313. - PMC - PubMed
    1. Alonso G, Phan V, Guillemain I, Saunier M, Legrand A, Anoal M, Maurice T. Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. 2000;97:155–170. - PubMed
    1. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron. 2002;34:399–410. - PubMed
    1. Ball JR, Kiloh LG. A controlled trial of imipramine in treatment of depressive states. Br Med J. 1959;2:1052–1055. - PMC - PubMed
    1. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. 2008;1211:37–43. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp